Cresco Labs Closes Pennsylvania Dispensary Deal

CHICAGO – Cresco Labs Inc. announced the closing of its acquisition of 100% of the outstanding equity interests in PharmaCann Penn, LLC for an aggregate consideration of $50 million. The deal covers nine operational retail medical Cannabis dispensaries in the Keystone State – the transaction immediately accretive to revenue, margins and cash flow.

The integration was formally announced in the company’s Q2 2026 earnings release, which confirmed Cresco had begun supporting operations of nine Pennsylvania dispensaries under a management services agreement. Formal ownership transfer remains pending Pennsylvania state regulatory approval.

Pennsylvania ranks as the second-largest medical Cannabis market in the United States, generating more than $1.1 billion in annual sales last year, according to the release. Following the closing, Cresco stated it will become the top retailer of medical Cannabis to patients across the state. The company already holds the leading wholesale position in Pennsylvania and said the combination of expanded retail doors with its existing cultivation and wholesale operations strengthens its scale in the market.

“Without rebranding a single dispensary, we’ve increased the store’s gross profit dollars by 11% compared to pre-acquisition baselines,” noted Charlie Bachtell, Cresco’s CEO. “This means the largest value unlock is still ahead of us as we introduce the Sunnyside brand and deploy our complete operating playbook after we close and take ownership.”

Cresco currently holds the No. 1 branded share position in Pennsylvania at 16%, and its Sunnyside stores generate roughly 30% more revenue per location than the state average. Nine additional stores, once fully integrated, are expected to extend that lead.

Today, Pennsylvania operates as a medical-only Cannabis market, with adult-use legislation stalled due to a partisan standoff in Harrisburg. Bachtell described the situation as “a matter of how and when, not if,” though no specific timeline was provided.

Overall, this deal is textbook MSO consolidation:

• acquire before the market re-rates,
• operate under a management services agreement to prove the value,
• then rebrand, and
• close after regulatory sign-off.

At roughly $5.6 million per store, the price is reasonable given Cresco’s demonstrated ability to outperform state averages from the very first quarter of integration. Near-term returns on these nine stores will rest on how much volume Cresco can extract from the medical market for as long as adult-use remains off the table. At 16% branded share and growing, the company is building exactly the kind of deep structural advantage that translates into durable pricing power, and into a formidable position whenever Pennsylvania’s adult-use framework eventually arrives.